Research Analysts Set Expectations for DNLI FY2026 Earnings

Denali Therapeutics Inc. (NASDAQ:DNLI) – Research analysts at HC Wainwright increased their FY2026 earnings estimates for Denali Therapeutics in a research note issued on Tuesday, January 7th. HC Wainwright analyst A. Fein now forecasts that the company will earn ($0.58) per share for the year, up from their previous forecast of ($0.69). HC Wainwright currently has a “Buy” rating and a $87.00 target price on the stock. The consensus estimate for Denali Therapeutics’ current full-year earnings is ($2.71) per share. HC Wainwright also issued estimates for Denali Therapeutics’ FY2027 earnings at $1.82 EPS.

Denali Therapeutics (NASDAQ:DNLI) last announced its earnings results on Wednesday, November 6th. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.03). During the same quarter in the previous year, the business posted ($0.72) earnings per share.

A number of other research analysts have also issued reports on the stock. Stifel Nicolaus upgraded shares of Denali Therapeutics from a “hold” rating to a “buy” rating and set a $37.00 target price on the stock in a report on Monday, December 16th. Jefferies Financial Group raised their target price on shares of Denali Therapeutics from $40.00 to $45.00 and gave the stock a “buy” rating in a research report on Friday, November 1st. Cantor Fitzgerald downgraded Denali Therapeutics from an “overweight” rating to a “neutral” rating in a report on Monday, October 7th. JPMorgan Chase & Co. decreased their price objective on Denali Therapeutics from $28.00 to $24.00 and set an “overweight” rating on the stock in a report on Tuesday. Finally, Raymond James reiterated a “market perform” rating on shares of Denali Therapeutics in a research note on Thursday, October 10th. Two analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $38.91.

Denali Therapeutics Stock Down 10.1 %

Shares of NASDAQ:DNLI opened at $19.10 on Thursday. The company has a market capitalization of $2.75 billion, a P/E ratio of -6.92 and a beta of 1.39. Denali Therapeutics has a 52-week low of $14.56 and a 52-week high of $33.33. The stock’s fifty day simple moving average is $24.13 and its 200-day simple moving average is $24.83.

Insider Activity

In related news, insider Alexander O. Schuth sold 15,558 shares of Denali Therapeutics stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $29.91, for a total transaction of $465,339.78. Following the transaction, the insider now owns 178,066 shares in the company, valued at approximately $5,325,954.06. The trade was a 8.04 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Vicki L. Sato sold 1,020 shares of the stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $30.00, for a total value of $30,600.00. Following the completion of the sale, the director now owns 111,056 shares of the company’s stock, valued at approximately $3,331,680. This represents a 0.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 104,518 shares of company stock valued at $2,576,982 in the last three months. Corporate insiders own 7.90% of the company’s stock.

Hedge Funds Weigh In On Denali Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. grew its position in Denali Therapeutics by 6.5% in the third quarter. JPMorgan Chase & Co. now owns 235,386 shares of the company’s stock valued at $6,857,000 after acquiring an additional 14,324 shares in the last quarter. Principal Financial Group Inc. grew its holdings in Denali Therapeutics by 13.8% during the 3rd quarter. Principal Financial Group Inc. now owns 1,238,476 shares of the company’s stock valued at $36,076,000 after purchasing an additional 149,939 shares in the last quarter. Franklin Resources Inc. increased its stake in Denali Therapeutics by 3.8% during the 3rd quarter. Franklin Resources Inc. now owns 80,041 shares of the company’s stock worth $2,148,000 after buying an additional 2,901 shares during the period. Barclays PLC lifted its holdings in Denali Therapeutics by 101.4% in the 3rd quarter. Barclays PLC now owns 255,883 shares of the company’s stock worth $7,454,000 after buying an additional 128,823 shares in the last quarter. Finally, Nomura Asset Management Co. Ltd. purchased a new position in Denali Therapeutics in the 3rd quarter valued at about $1,894,000. 92.92% of the stock is owned by institutional investors and hedge funds.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.